GROWTH HORMONE AXIS / FAQ
Questions From the Research Record
Direct, citation-anchored answers to what people most often ask about these four GH-axis compounds.
What is CJC-1295?
CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH), chemically modified to resist rapid breakdown by the enzyme DPP-IV. Its most common research form is also bonded to serum albumin — the "DAC" chemistry — which extends a single dose's effect on growth hormone and IGF-1 to multiple days [4][7]. It is not approved for human use by the FDA or any regulator and is sold only as a research chemical.
What does CJC-1295 do?
In published human pharmacology studies, single doses of CJC-1295 produced dose-dependent 2- to 10-fold increases in growth hormone lasting six or more days, and 1.5- to 3-fold increases in IGF-1 lasting 9-11 days, while the body's normal pulsatile pattern of GH release continued unchanged on top of the new, higher baseline [4][5]. These findings come from small studies in healthy adults, not from any approved clinical use.
Is CJC-1295 safe?
CJC-1295 has never been approved by the FDA or any major regulator, and published human evidence is limited to a small number of pharmacology studies from the mid-2000s — there is no large or long-term safety trial [4]. Researchers flag mechanism-based cautions around sustained IGF-1 elevation, fluid retention, and, per 2024 FDA compounding-committee briefing materials, immunogenicity concerns [1]. This page does not make a safety determination for any individual — see the CJC-1295 page for the full cited discussion.
How much CJC-1295 should I take?
This site does not recommend a dose. In the cited human pharmacology studies, researchers used single subcutaneous doses of 30, 60, or 90 micrograms per kilogram to characterize CJC-1295's effect on GH and IGF-1 in healthy volunteers [4][5] — those figures describe what was studied in a controlled research setting, not a recommendation for anyone outside that trial context.
What is CJC-1295 / Ipamorelin good for?
CJC-1295/Ipamorelin is a research combination, not an approved product — it pairs a GHRH analog with a selective ghrelin-receptor agonist on the theory that engaging both pathways produces a larger GH pulse than either alone, a mechanism supported by older receptor co-activation studies [10]. No controlled trial has tested what the fixed combination is "good for"; research-use communities most often discuss it in the context of sleep, recovery, and gradual body-composition change, and those reports are anecdotal, not clinical evidence.
What are the bad side effects of CJC-1295 and Ipamorelin?
Community reports most consistently describe injection-site reactions and transient water retention as the mildest and most common complaints, with facial flushing, tingling in the hands, and grogginess reported less often — all anecdotal, not clinical findings. From the cited literature, the more serious mechanism-based cautions are increased blood glucose from reduced insulin sensitivity (the chief concern identified across the GH-secretagogue drug class) and fluid-retention-related effects like carpal-tunnel-type symptoms in people prone to swelling or cardiac strain [9].
How long do CJC-1295 and Ipamorelin take to work?
CJC-1295 (DAC) and ipamorelin work on very different timescales, which is part of why the combination is mechanistically complicated. CJC-1295's own pharmacology shows a single dose elevating GH for six or more days and IGF-1 for 9-11 days [4], while ipamorelin's pharmacokinetic profile shows a roughly two-hour half-life and a GH pulse peaking about 40 minutes after dosing [14]. No study has directly timed the combined effect.
How many mg of CJC-1295 and Ipamorelin should I take?
This site does not recommend a dose for either compound, alone or combined. The cited human studies used research doses expressed per body weight — for example, 30-90 micrograms per kilogram for CJC-1295 [4][5] and doses up to 140.45 nmol/kg for ipamorelin in pharmacokinetic testing [14] — figures that describe what was studied under controlled conditions, not guidance for self-administration.
What is ipamorelin?
Ipamorelin is a synthetic five-amino-acid peptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that selectively activates the ghrelin receptor (GHS-R1a), triggering growth hormone release. Its defining feature relative to older GH-releasing peptides is that it does so without meaningfully raising cortisol or prolactin, even at high doses in animal studies [15]. It is not approved for human use and is sold only as a research chemical.
What does ipamorelin do for you?
In its one controlled human trial — a Phase 2 study in 114 adults recovering from bowel surgery — ipamorelin did not significantly speed the return of tolerated eating compared with placebo [13]. In a 2024 ferret study, it reduced chemotherapy-associated weight loss by about 24% during the delayed phase, though it had no anti-emetic effect [11]. Research-use community reports, which are anecdotal and not clinical evidence, most often describe improved sleep.
What is ipamorelin peptide?
Ipamorelin is classified as a growth hormone secretagogue — specifically, a selective agonist of the ghrelin/growth-hormone-secretagogue receptor (GHS-R1a). It was derived from an earlier, less selective compound (GHRP-1) and is studied for its ability to trigger a pulse of growth hormone release through that receptor [15].
What are the risks of ipamorelin?
Because ipamorelin raises growth hormone and downstream IGF-1, researchers flag a mechanism-based (not proven) concern around malignancy in people with active or recent cancer [15]. Ghrelin-receptor agonists as a class also stimulate appetite, which matters for people managing weight or eating-disorder history. The most direct cardiovascular safety signal in the literature is preclinical: a 28-day study of a related, not identical, ghrelin-receptor agonist found dose-dependent heart-muscle damage in rats [12]. Beyond the single Phase 2 surgical trial, there is no long-term human safety database for ipamorelin [13].
What is tesamorelin?
Tesamorelin is a synthetic 44-amino-acid analog of growth-hormone-releasing hormone (GHRH), chemically stabilized against rapid breakdown. It is the only compound in this guide with FDA approval — cleared in 2010 specifically to reduce excess abdominal fat in adults with HIV-associated lipodystrophy [16].
What does tesamorelin do?
Tesamorelin stimulates the pituitary gland to release growth hormone in its normal pulsatile pattern, which raises IGF-1 and promotes fat breakdown with a documented preference for visceral (abdominal, around-the-organs) fat. In its pivotal trial, tesamorelin produced a treatment effect of -42 cm2 in visceral fat over six months [17], and a 2026 meta-analysis of five trials found an average -27.71 cm2 reduction along with reduced liver fat and increased lean mass [8].
How does tesamorelin work?
Tesamorelin binds the GHRH receptor on pituitary somatotroph cells, activating the same signaling cascade as natural GHRH to stimulate growth hormone synthesis and release. The resulting GH and downstream IGF-1 promote lipolysis with a preference for visceral adipose tissue over other fat depots — the mechanistic basis for its approved use in reducing abdominal fat accumulation [8][17].
Will tesamorelin help me lose belly fat?
This site does not offer individual medical guidance. What the cited trial record shows is that in adults with HIV-associated lipodystrophy, tesamorelin produced significant reductions in visceral (abdominal) fat — a treatment effect of -42 cm2 in one pivotal trial [17], sustained at roughly -18% over 52 weeks in a longer program, with fat reaccumulating after stopping [19]. Tesamorelin's FDA approval is specific to that HIV population; its effect in other populations is not established by the same level of evidence.